VAXCYTE, INC. (PCVX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $148.00K; Additional Paid in Capital, Common StockUSD $5.53B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-7.55M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $147.00K; Additional Paid in Capital, Common StockUSD $5.48B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-6.83M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $134.00K; Additional Paid in Capital, Common StockUSD $4.84B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.59M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $133.00K; Additional Paid in Capital, Common StockUSD $4.80B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $856.00K.
VAXCYTE, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $148.00K | $5.53B | $-7.55M | $-2.76B | $2.76B | 3 month · $41.24M | (m) |
| 2026-03-31 | $0.00 | $147.00K | $5.48B | $-6.83M | $-2.48B | $3.00B | 3 month · $37.96M | (m) |
| 2025-12-31 | $0.00 | $134.00K | $4.84B | $1.59M | $-2.15B | $2.69B | 12 month · $138.84M | (m) |
| 2025-09-30 | $0.00 | $133.00K | $4.80B | $856.00K | $-1.91B | $2.89B | 3 month · $35.31M | (m) |
| 2025-06-30 | $0.00 | $133.00K | $4.77B | $-1.89M | $-1.70B | $3.07B | 3 month · $36.93M | (m) |
| 2025-03-31 | $0.00 | $132.00K | $4.73B | $-322.00K | $-1.53B | $3.20B | 3 month · $30.61M | (m) |
| 2024-12-31 | $0.00 | $128.00K | $4.70B | $-3.87M | $-1.39B | $3.31B | 12 month · $84.82M | (m) |
| 2024-09-30 | $0.00 | $127.00K | $4.67B | $139.00K | $-1.25B | $3.42B | 3 month · $21.27M | (m) |
| 2024-06-30 | $0.00 | $114.00K | $3.13B | $1.81M | $-1.15B | $1.99B | 3 month · $21.56M | (m) |
| 2024-03-31 | $0.00 | $112.00K | $3.00B | $2.89M | $-1.02B | $1.98B | 3 month · $17.63M | (m) |
| 2023-12-31 | $0.00 | $98.00K | $2.16B | $179.00K | $-924.39M | $1.24B | 12 month · $48.76M | (m) |
| 2023-09-30 | $0.00 | $98.00K | $2.15B | $-2.29M | $-743.59M | $1.40B | 3 month · $13.22M | (m) |
| 2023-06-30 | $0.00 | $97.00K | $2.09B | $-2.52M | $-650.93M | $1.43B | 3 month · $12.54M | (m) |
| 2023-03-31 | $0.00 | $84.00K | $1.53B | $47.00K | $-582.59M | $944.77M | 3 month · $9.65M | (m) |
| 2022-12-31 | $0.00 | $82.00K | $1.48B | $-361.00K | $-522.13M | $953.61M | 12 month · $23.65M | 12 month · $45.81M |
| 2022-09-30 | $0.00 | $64.00K | $803.98M | $-657.00K | $-444.08M | $359.31M | 3 month · $6.65M | (m) |
| 2022-06-30 | $0.00 | $62.00K | $753.50M | $-904.00K | $-386.16M | $366.50M | 3 month · $5.89M | (m) |
| 2022-03-31 | $0.00 | $59.00K | $697.94M | $-833.00K | $-337.63M | $359.54M | 3 month · $4.10M | (m) |
| 2021-12-31 | $0.00 | $56.00K | $582.84M | $-241.00K | $-298.64M | $284.02M | 12 month · $10.73M | (m) |
| 2021-09-30 | (m) | $56.00K | $575.99M | $-12.00K | $-270.08M | $305.96M | 3 month · $2.94M | (m) |
| 2021-06-30 | (m) | $55.00K | $560.44M | $-8.00K | $-243.46M | $317.02M | 3 month · $2.77M | (m) |
| 2021-03-31 | (m) | $54.00K | $546.71M | $-47.00K | $-219.78M | $326.94M | 3 month · $1.86M | (m) |
| 2020-12-31 | (m) | $54.00K | $544.35M | (m) | $-198.56M | $345.84M | 12 month · $5.43M | (m) |
| 2020-09-30 | (m) | $54.00K | $541.85M | (m) | $-177.83M | $364.07M | 3 month · $1.84M | 3 month · $72.00K |
| 2020-06-30 | (m) | $54.00K | $539.97M | (m) | $-156.81M | $383.21M | 3 month · $1.29M | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-132.97M | 3 month · $372.00K | (m) |
| 2019-12-31 | (m) | $7.00K | $2.97M | (m) | $-109.35M | $-106.37M | 12 month · $1.19M | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $-92.16M | 3 month · $266.00K | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-81.48M | 3 month · $278.00K | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-71.11M | 3 month · $266.00K | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-57.73M | 12 month · $749.00K | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $-29.13M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |